10 Worst States for Depression Among the College Educated
5 New DOL Fiduciary Rule Standards Delay Facts
Let Clients Figure the Retirement Funding Catastrophe Out for Themselves
President Donald Trump told Republican senators on Tuesday he supports an Affordable Care Act individual major medical market stabilization bill offered by Republican Lamar Alexander and Democrat Patty Murray, which may help bolster support for the tax-cut legislation headed for a vote this week.
Sen. Mike Rounds of South Dakota quoted Trump as telling Republican senators, “I support the Alexander-Murray bill.”
“He actually made it very clear that he supported the Alexander-Murray bill,” Rounds said of the president’s remarks during a luncheon meeting with senators. “He sees it as a transition away from Obamacare.”
Alexander of Tennessee said he was “delighted” that the president didn’t put any conditions on his support for the legislation.
Hot Medical Stocks To Own Right Now: Ring Energy, Inc.(REI)
- [By Monica Gerson]
Ring Energy Inc (NYSE: REI) is projected to post a quarterly loss at $0.05 per share on revenue of $7.92 million.
Gain Capital Holdings Inc (NYSE: GCAP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $100.39 million.
Hot Medical Stocks To Own Right Now: Celldex Therapeutics Inc(CLDX)
- [By Paul Ausick]
Celldex Therapeutics Inc. (NASDAQ: CLDX) traded down nearly 65% Monday to post a new 52-week low of $0.76 after closing Friday at $2.15. The stock’s 52-week high is $3.42. Volume was about 25 times the daily average of around 1.4 million shares. The company’s breast cancer drug failed to meet a phase 2 study’s primary endpoint.
- [By Paul Ausick]
Celldex Therapeutics Inc. (NASDAQ: CLDX) fell by about 7.6% Wednesday to post a new 52-week low of $0.72 after closing at $0.79 on Tuesday. The 52-week high is $3.42. Volume of about 9 million was more than four times the daily average of about 2 million. The company continues to get beaten up following a failed breast cancer drug study.
- [By Lisa Levin]
In trading on Tuesday, healthcare shares fell by 0.57 percent. Meanwhile, top losers in the sector included Amicus Therapeutics, Inc. (NASDAQ: FOLD), down 9 percent, and Celldex Therapeutics, Inc. (NASDAQ: CLDX), down 9 percent.
- [By WWW.KIPLINGER.COM]
Celldex Therapeutics, Inc. (CLDX) is the first of the major biotech stocks scheduled to release an update on a pretty important drug this quarter; look for news on Oct. 8 concerning melanoma treatment glembatumumab vedotin. And thats a firm date too. Celldex is slated to present an update on the therapy at the European Society for Medical Oncology Congress.
- [By Todd Campbell]
The ability to develop game-changing new drugs that revolutionize patient care could cause shares in Axovant Sciences (NYSE:AXON), Celldex Therapeutics (NASDAQ:CLDX), and Esperion Therapeutics (NASDAQ:ESPR) to soar. However, success may be tough to come by, and that makes investing in these stocks a boom or bust proposition.
Hot Medical Stocks To Own Right Now: Aimia Inc. (GAPFF)
- [By SEEKINGALPHA.COM]
Aimia (OTCPK:GAPFF) (TSX: AIM, AIM.PR.A, AIM.PR.B, AIM.PR.C)
As some background, we are intimately familiar with Aeroplan and Air Canada (OTCQX:ACDVF) not just as investors but as extraordinarily heavy consumers. As both an Air Canada top tier elite and Aeroplan top tier member I generate well in excess of 1.5 million Aeroplan miles annually, half from flying Air Canada and its partners and the other half from spending. As consumers we were concerned with Air Canada’s decision (though we expect more details to come out that will alleviate these concerns) but as investors we understand that the fundamental business model of mileage programs are incredibly attractive and that Aimia presents an incredibly rare and lucrative investment opportunity for the investor discerning enough to dig into the company.
Hot Medical Stocks To Own Right Now: iShares Mortgage Real Estate Capped (REM)
- [By Donald van Deventer]
The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include: